Análisis de la acción TriSalus Life Sciences Inc (TLSI)

$3.890

+0.458 (+11.78%)Al cierre

Loading chart…

Máximo: 4.000
Apertura: 3.600
Precio medio ponderado por volumen: 3.83
Volumen: 232.27K
Capitalización: 156.44M
Mínimo: 3.600
Importe: 889.61K
EV/EBITDA, TTM: -3.19

TriSalus Life Sciences, Inc. is an oncology-focused medical technology company. It is seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technological applications. Its delivery method, Pressure-Enabled Drug Delivery (PEDD), modulates pressure and flow within blood vessels to improve intravascular therapeutic delivery into tumors, thereby increasing the likelihood of tumor response in comparison to conventional delivery technologies. Its on-market TriNav Infusion System using PEDD technology, is being used for interventional radiology procedures, commonly transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or in patients with liver metastases. TriNav is a device with a novel (PEDD) delivery method.

trisaluslifesci.com

Análisis de IA of TriSalus Life Sciences Inc (TLSI)

Mantener

TriSalus Life Sciences Inc is currently not a strong buy due to its low current price of $3.63 and an RSI of 36.448, indicating potential oversold conditions. However, the stock has a significant upside potential with analysts projecting a price target of $12, which suggests a potential upside of over 230%. The main risk is its high debt to equity ratio of 504.81%, indicating financial instability that could affect future performance.

Métricas de valoración

El PER previsto actual de TriSalus Life Sciences Inc (TLSI) es 0.00, frente a su media de 5 años de -5.35.

PER previsto

Valor razonable

Media 5A P/E

-5.35

P/E actual

0.00

Sobrevalorada

0.43

Infravalorada

-11.14

EV/EBITDA previsto

Valor razonable

Media 5A EV/EBITDA

-11.34

EV/EBITDA actual

-3.19

Sobrevalorada

10.81

Infravalorada

-33.50

Precio/ventas previsto

Valor razonable

Media 5A P/S

3.76

P/S actual

2.88

Sobrevalorada

6.72

Infravalorada

0.79

Escenarios de precio de Alphio AI para TLSI

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

Alcista

Alcista · 25%TLSI

$9.17

Precio del escenario

Base

Base · 50%TLSI

$6.96

Precio del escenario

Bajista

Bajista · 25%TLSI

$5.01

Precio del escenario